Abstract:Abstract Selection of therapeutic targets and modalities is of fundamental importance in drug discovery, as it can have a direct impact on the economics of drug discovery as well as its success rate. With the advancement of chem-bio and proteomics methods together with advent of artificial intelligence, the scope of the druggable proteome is expanding. The choice of drug targets gains further importance as we link it to potential clinical efficacy and safety, genetic variation and patient populations. Drug targets are often selected based on inadequate understanding of target biology, tractability by existing toolbox of therapeutic modalities and insufficient insight into possible clinical outcome. We have developed an “Atlas of Therapeutic Targets”, an interactive resource that provides classification of drug target families with linked information on clinical and investigational drugs. The atlas also provides key insights and score for tractability of targets with various therapeutic modalities. Particularly, our scoring system grades the targets on dimensions such as ligandability, involvement in protein-protein complexes, structural disorder, hotspot analysis and cross-referencing with known targets, thus yielding a total tractability score of 1-10. Dissection of targets based on such dimensions, enables critical evaluation therapeutic modalities as well tools and methodologies needed for their conversion into successful drug discovery programs. We curate 900+ human drug targets, analysis of which indicates the continued dominance of privileged target families across disease areas, but also the growth of novel first-in-class mechanisms. This atlas will be available as a resource for the wide drug discovery community. Citation Format: Ivan Babic, Elmar Nurmemmedov. Atlas of therapeutic targets: Evolution of druggable proteome [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3545.

Unexplored Therapeutic Opportunities in the Human Genome

The human genome and drug discovery after a decade. Roads (still) not taken

Target Discovery and Validation in the Post-Genomic Era

From target discovery to clinical drug development with human genetics

Therapeutic targets: Progress of their exploration and investigation of their characteristics (vol 58, pg 259, 2006)

Disease coverage of human genome-wide association studies and pharmaceutical research and development

Exploiting Chemical Probes for Identifying Drug Target Proteins

Recent advances and method development for drug target identification

Exploration of Target Spaces in the Human Genome for Protein and Peptide Drugs

Overview of the Knowledge Management Center for Illuminating the Druggable Genome

Validating therapeutic targets through human genetics

Progress and Problems in the Exploration of Therapeutic Targets.

Abstract 3545: Atlas of therapeutic targets: Evolution of druggable proteome

GPCRomics: An Approach to Discover GPCR Drug Targets

The human genome project: a historical perspective

Using human genetics to improve safety assessment of therapeutics

Trends in Exploration of Therapeutic Targets

Illuminating function of the understudied druggable kinome

Informatic challenges and advances in illuminating the druggable proteome

omicSynth: An open multi-omic community resource for identifying druggable targets across neurodegenerative diseases

Development of a human genetics-guided priority score for 19,365 genes and 399 drug indications